Lung Transplantation Guidelines For Selection Milpark Hospital Transplant Unit Johannesburg, South Africa SATS Controversies Meeting May 2011.

Slides:



Advertisements
Similar presentations
HEART-LUNG TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24:
Advertisements

HEART-LUNG TRANSPLANTATION
Definition of COPD COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual.
Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Pulmonary Function Testing
LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
Referral to specialist respiratory service BTS guidelines, March 2008 Nawar D Bakerly.
SYMPTOM CONTROL FOR ADVANCED RESPIRATORY DISEASE
Ethical dilemma in organ allocation for lung transplantation John-David Aubert Respiratory Division Lausanne-Geneva Lung Tx Centre - Switzerland ERS Vienna.
Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.
Extracorporeal Membrane Oxygenation Following Lung Transplantation in Adult ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor.
Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp
Applied Epidemiology Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) By Chris Callan 23 April 2008.
LUNG TRANSPLANTATION ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor of Surgery Division of Cardiothoracic Surgery King Abdulaziz.
By: E. Salehifar Clinical Pharmacist
Managing end stage COPD in primary care
LUNG TRANSPLANTATION and PULMONARY FIBROSIS Maria L. Padilla, MD Associate Prof. of Medicine Director of ILD/IPF and Advanced Lung Disease Program MSSM/MSMC.
Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.
Overview of Lung Transplantation
HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
LUNG TRANSPLANTATION CURRENT STATUS Iskander Al-Githmi, MD, FRCSC-GS, FRCSC -Ts, FRCSC-CDs, FACS, FCCP Division of Cardiothoracic Surgery King Abdulaziz.
Approach to bronchiectasis
SSA Hearing on Compassionate Allowances Janet N Scheel MD November 9,2010.
CM-1 Clinical Transplantation Lung Howard University Hospital Department of Transplantation Clive O. Callender, MD. Arturo Hernandez, MD.
An International Case Study of Lung Transplantation
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
IDIOPATHIC PULMONARY FIBROSIS. BASICS in IPF CLASSIFICATION OF INTERSTITIAL LUNG DISEASE OR DIFFUSE PARENCHYMAL LUNG DISEASE.
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
End stage Lung Disease: What is it and what are some treatment options? NC Cardiopulmonary Rehabilitation Association Meeting March 14, 2014;
實習生 : 中山醫 李佳靜 指導老師 : 陳燕慈 營養師 The Relationship of BMI and Lung Transplant Recipients 1.
يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11يکشنبه، 2015/10/11 بسم الله الرحمن الرحیم با سلام.
Prognostic Indicator Guidance May 2011 Dr Peter Nightingale.
LUNG TRANSPLANTATION 2012 דר ' לקסר אורי מכון הראה בית החולים האוניברסיטאי הדסה.
Risk Assessment Farrokh Alemi, Ph.D.. Session Objectives 1.Discuss the role of risk assessment in the TQM process. 2.Describe the five severity indices.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
Exercise Testing – clinical utility Sudhir Rao Respiratory registrar.
HEART-LUNG TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):
1 Vaccines Contraindications. Contraindications to any routine active immunization procedure An acute febrile illness, malaise, cough, diarrhea, or other.
Ethics and Organ Transplantation Richard L Elliott, MD, PhD Professor and Director Medical Ethics and Professionalism Mercer University School of Medicine.
Chronic Obstructive Pulmonary Disease Austin Paul K.
Is the failure of pulmonary gas exchange to maintain the normal arterial O2 and CO2 level. It is divided in to type I and II in relation to the presence.
LUNG TRANSPLANTATION Adult Recipients 2014 JHLT Oct; 33(10):
PFF Teal = MAIN COLORS PFF Green = Light Green = Red = HIGHLIGHT COLORS Light Grey = Dark Grey =
Organ Transplantation. Why is Organ Donation So Important?  There are around 1600 people currently waiting for a transplant in Australia  In 2012, 354.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Attaran D, Mashhad university of medical sciences.
Restrictive lung disease
E FFECTS OF C ARDIOVASCULAR D RUGS ON M ORTALITY IN S EVERE C HRONIC O BSTRUCTIVE P ULMONARY D ISEASE A T IME -D EPENDENT A NALYSIS Magnus P. Ekstrom,
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis N ENGL J MED. May 18, /NEJMoa Talmadge E. King, Jr., M.D.,
Dr Julius Cairn. Introduction - update COPD Exacerbations Pulmonary rehabilitation Lung cancer - NSCLC Treatments for patients with limited lung function.
Azithromycin – for better or worse in chronic lung infection? Professor Emma Baker Professor of Clinical Pharmacology St George's, University of London.
CM-1 Current Status of Lung Transplantation Jeff Golden, MD Professor of Clinical Medicine and Surgery Medical Director, Lung Transplantation University.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL R2 이윤정 Richard A. Belkin, Noreen R. Henig, Lianne G. Singer, Cecilia Chaparro,
Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient [ CHEST JULY 2015 ] 호흡기내과 R4. 박세정.
R. Papani, A. G. Duarte, Y-L. Lin, G. Sharma
The Registry of the International Society for Heart and Lung Transplantation: Thirty- second Official Adult Lung and Heart-Lung Transplantation Report—2015;
Palliative Care Education Module
11/11/16 Kirstie Wallace/Hazel Muse Transplant Co-ordinators
In Cystic Fibrosis Patients Receiving Pancreatic Enzymes
Patient involvement in ERS Task Forces
Figure 3. The majority of patients have obstructive lung function
Effect of volume reduction on lung transplant timing and selection for chronic obstructive pulmonary disease  Joseph E. Bavaria, MD, Alberto Pochettino,
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010
LUNG TRANSPLANTATION CURRENT STATUS
David P. Mason, MD, Jeevanantham Rajeswaran, MS, Sudish C
THE AUSTRALIA AND NEW ZEALAND CARDIOTHORACIC ORGAN TRANSPLANT REGISTRY
Experience with lung transplantation
UK Cystic Fibrosis Registry Annual Data Report 2017
New Models of Care in Idiopathic Pulmonary Fibrosis
Presentation transcript:

Lung Transplantation Guidelines For Selection Milpark Hospital Transplant Unit Johannesburg, South Africa SATS Controversies Meeting May 2011

South African Guidelines based on : ATS - International Guidelines for the selection of Lung Transplant Candidates – 1998 ATS - International Guidelines for the selection of Lung Transplant Candidates – 1998 ISHLT – Update – 2006 ISHLT – Update – 2006 GENERAL GENERAL -Patient should be receiving or have received maximal medical therapy, but nevertheless have declining function, with a limited life expectancy ( <50% year survival). -The patient should have ambulatory and rehabilitation potential. -A satisfactory psycho-social profile with support systems is essential.AGE -Older patients have a significantly worse prognosis. -HLT<55 years. - BSLT <60 years. - SLT <65 years. BMI - 18 – 30%

Lung Transplantation as the sole form of therapy is potentially indicated in any irreversible condition, resulting in either one or both of the following disease entities: END STAGE RESPIRATORY FAILURE.END STAGE RESPIRATORY FAILURE. ( ICD 10 CODE: J96.1) PULMONARY ARTERIAL HYPERTENSION.PULMONARY ARTERIAL HYPERTENSION. ( ICD 10 CODE: I27.0) (ICD 10 CODE: Q20 – 28) Refer for Assessment at this Stage and Exclude Unsuitable Recipients following Review of Disease Specific Guidelines

A.End Stage Respiratory Failure Conditions grouped as follows: COPD (ICD 10 Code: J40 -J46) COPD (ICD 10 Code: J40 -J46) - Acquired. - Congenital (Alpha1 – Antitrypsin def.). Idiopathic Pulmonary Fibrosis (IPF). (ICD 10 Code: J80-J84) Idiopathic Pulmonary Fibrosis (IPF). (ICD 10 Code: J80-J84) Infective/Inflammatory. (ICD 10 Code: J47.xx, J60-J70,J85-J86 E84 & other) Infective/Inflammatory. (ICD 10 Code: J47.xx, J60-J70,J85-J86 E84 & other) - Cystic Fibrosis (CF). - Cystic Fibrosis (CF). - Bronchiectasis. - Bronchiectasis. - Sarcoidosis. - Sarcoidosis. - Other e.g. – LAM etc. - Other e.g. – LAM etc. B.Pulmonary Hypertension - Primary (PPH). - Primary (PPH). - Secondary. - Secondary.

Disease Specific Criteria COPD FEV¹ <25% of predicted. FEV¹ <25% of predicted. PaCO² > 55/PHT. PaCO² > 55/PHT. Progressive deterioration on Domiciliary Oxygen. Progressive deterioration on Domiciliary Oxygen. Frequent admissions with declining function. Frequent admissions with declining function. Patients with a high BODE index. Patients with a high BODE index. Patients not better served by LVRS. Patients not better served by LVRS.

Disease Specific Criteria – cont. IPF Symptomatic disease. Symptomatic disease. Exercise desaturation. Exercise desaturation. VC < 60 – 75% predicted. VC < 60 – 75% predicted. DLCO < 50 – 60% predicted. DLCO < 50 – 60% predicted.

Disease Specific Criteria – cont. Infective/Inflammatory (CF) FEV¹ < 30% predicted. FEV¹ < 30% predicted. High Risk Patients: High Risk Patients: -Young Females with a rapidly declining FEV¹. -Weight Loss. -Frequent Infective Exacerbations. -Haemoptysis.

Disease Specific Criteria – cont. PPH NYHA Class III/IV on optimal treatment – Epoprostanol/Sildenafil/Bosentan. NYHA Class III/IV on optimal treatment – Epoprostanol/Sildenafil/Bosentan. Declining Functional Capacity. Declining Functional Capacity.

Disease Specific Criteria – cont. EISENMENGERS SYNDROME (2° PAT) NYHA Class III/IV and Declining Functional Capacity. NYHA Class III/IV and Declining Functional Capacity.

Contra-indications HIV+ve/AIDS.HIV+ve/AIDS. Hepatitis B, Ag+ve.Hepatitis B, Ag+ve. Hepatitis C with biopsy proven liver disease.Hepatitis C with biopsy proven liver disease. Active malignancy.Active malignancy. Dysfunction of one or more major organ. systems other than lungs, e.g. renal failure.Dysfunction of one or more major organ. systems other than lungs, e.g. renal failure.

Relative Contra-indications In combination – increases risk of Tx In combination – increases risk of Tx Severe Osteoporosis.Severe Osteoporosis. Hypertension.Hypertension. Diabetes Mellitus.Diabetes Mellitus. Peptic Ulcer Disease.Peptic Ulcer Disease. Musculo-skeletal Disease eg. Kypho-scoliosisMusculo-skeletal Disease eg. Kypho-scoliosis Long term, high dose corticosteroids.Long term, high dose corticosteroids. Poor nutritional status.Poor nutritional status. Substance abuse.Substance abuse. Psychological disorders.Psychological disorders. Mechanical ventilation.Mechanical ventilation. Microbial colonisation.Microbial colonisation. T.B. (untreated).T.B. (untreated).

Conclusions Most patients with diagnosis of IPF/UIP SHOULD be considered for EARLY transplant listing – due to rapid progression of disease. Most patients with diagnosis of IPF/UIP SHOULD be considered for EARLY transplant listing – due to rapid progression of disease. Very FEW patients with COPD/Airway obstruction WOULD be considered suitable for listing – advanced age with co-morbid disease. Very FEW patients with COPD/Airway obstruction WOULD be considered suitable for listing – advanced age with co-morbid disease.

Conclusions Worldwide the percentage of patients Worldwide the percentage of patients undergoing transplantation with PAH is DIMINISHING due to improved prognosis with medical therapy. undergoing transplantation with PAH is DIMINISHING due to improved prognosis with medical therapy. A large and increasing percentage of CYSTIC FIBROSIS patients could potentially qualify for listing, although some patients currently elect not to follow this route. A large and increasing percentage of CYSTIC FIBROSIS patients could potentially qualify for listing, although some patients currently elect not to follow this route.

Conclusions Meeting disease specific criteria generally implies transplant ASSESSMENT is indicated. Meeting disease specific criteria generally implies transplant ASSESSMENT is indicated. Certain percentage will be excluded by Transplant Panel. It is in the interest of the Transplant Team to rigorously accept only ideal recipient. It is in the interest of the Transplant Team to rigorously accept only ideal recipient.